Verve Therapeutics

Vervians Patrick Flight, Steve Briscoe and Jessica McCoy, MCR, RAC, CCRP will be at the Verve booth (#6076) at American College of Cardiology’s #ACC25 this weekend. We’re looking forward to connecting with leaders in #cardiology and discussing how we’re working to protect the world from #cardiovascular disease through the development of single-course gene editing medicines. Come say hi!

Did you know that elevated Lipoprotein(a), or Lp(a), is a genetically inherited risk factor for #cardiovasculardisease? In honor of yesterday’s Lipoprotein(a) Awareness Day, we’re shining a light on this often-overlooked driver of heart disease. In our fourth installment of #VerveVocab, Liam Cornell, Ph.D., Jennifer Harsey Robinson, and Mrinal Kumar, discuss the risks of high blood levels of Lp(a) and highlight how Verve is attempting to?lower the risk of recurrent atherosclerotic cardiovascular disease events in patients with high Lp(a). Learn how you can help Family Heart Foundation raise awareness of elevated lipoprotein(a) here: https://lnkd.in/eAWU5skf #KnowLpa

Today, we celebrate an incredible milestone — the clearance of our investigational new drug application (IND) for VERVE-102 by the U.S. FDA in patients living with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD). VERVE-102 is an investigational in vivo #baseediting medicine designed to permanently turn off the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C). This represents an important step in our journey to advance a new class of in vivo gene editing medicines for people worldwide living with #cardiovasculardisease. Thank you to our incredible team for making this possible. Read more: https://lnkd.in/e5j5VwGS

We have a few annual traditions here at Verve, but none are quite as exhilarating as the one day a year that one lucky team of Vervians get to take over Sekar (Sek) Kathiresan’s office! Following their winning bid at our annual auction benefiting? Science from Scientists, an educational nonprofit organization, the HR team “rented out” our CEO’s office and turned it into a true crime scene. Thanks to the team for their contributions to such an impactful organization!

Congratulations to Ivan I., champion of our 2025 ping pong tournament! Ivan is a two-time champion having previously won in 2023. After some fierce (and friendly) competition, Ivan came out on top against finalist Yang Jiao, who took home the gold in 2024. Will 2026 bring a new finalist into the mix? Thanks to everyone who participated and served up their best! ??

We’re looking for a driven and talented professional to join our regulatory strategy team and help shape the future of #geneediting. This person will collaborate across teams to support early-stage programs, drive regulatory approvals, and keep our projects on track. If you’re ready to make an impact, learn more about the role and apply here:? https://lnkd.in/dw7ArKEs #NowHiring #RegulatoryAffairs #BiotechJobs #BostonJobs

On this #InternationalWomensDay, we’re proud to celebrate the women of Verve who #AccelerateAction in every part of their work from advancing clinical innovation and strengthening our culture to furthering our mission for cardiovascular patients in need. Together, we’re shaping a future where everyone has a seat at the table and the opportunity to lead. Here’s to the women who inspire us, today and every day. #IWD2025

On #EmployeeAppreciationDay, we say THANK YOU to our Vervians! Thank you for your dedication, resilience, and the heart you put into your work every day. Your commitment to innovation and the belief that we can make a difference for patients worldwide truly sets this team apart. Together, we can make a positive change for #cardiovascular health.

Our co-founder and CEO Sekar (Sek) Kathiresan, M.D., will be presenting at the Barclays Annual Global Healthcare Conference in Miami next week. Join us on Tuesday, March 11 as we discuss our latest company updates and upcoming milestones. Register here: https://lnkd.in/eFDgAqCA

Today, we announced pipeline progress and earnings for the fourth quarter and year ended December 31, 2024. Read the full announcement?including 2025 milestones?here: https://lnkd.in/exaF7ekG